# A proof-of-concept point-of-care test for the serodiagnosis of human amebic liver abscess

## TL;DR

Researchers developed a rapid, point-of-care test for diagnosing amebic liver abscess using whole blood, which could replace traditional ELISA tests in areas with limited medical resources.

## Contribution

A new point-of-care immunochromatographic test using whole blood for diagnosing amebic liver abscess is developed and validated.

## Key findings

- The ICT showed 100% sensitivity and 97.1% specificity, comparable to ELISA.
- The ICT demonstrated substantial agreement with ELISA (kappa value = 0.771).
- The ICT does not require serum separation, making it suitable for resource-limited settings.

## Abstract

Amebic liver abscess (ALA), caused by an extraintestinal invasion of the virulent protozoan Entamoeba histolytica, is important among parasitic causes of morbidity and mortality, especially in the tropics. Clinical symptoms, medical-imaging abnormalities of the liver and serological tests are normally made for supportive diagnosis. Serum-based enzyme-linked immunosorbent assay (ELISA) has been conventionally used for diagnosing ALA but is time-consuming and sophisticated equipment is required. Therefore, we sought to develop a new and rapid innovative point-of-care immunochromatographic test (ICT) that can use whole blood as an alternative to serum-based ELISA. An ICT tool using simulated whole-blood samples was developed for immunoglobulin G antibody detection, and its diagnostic efficiency was evaluated in comparison with serum-based ELISA.

Both methods were tested to assess their diagnostic performance using a total of 253 serum samples. These came from ALA patients (n = 13), healthy individuals (n = 40), and patients with other diseases (n = 200).

Amebiasis-ICT exhibited 100% (95% confidential interval (CI) [75.3–100.0]) sensitivity and 97.1% (95% CI [94.1–98.8]) specificity, whereas ELISA gave the same sensitivity (100% 95% CI [75.3 –100.0]) and slightly lower specificity (95.8% 95% CI [92.5–98.0]). There were no significant differences in sensitivity and specificity between the two tests (Exact McNemar’s test; p > 0.05), with Cohen’s kappa agreement 96.44% (κ-value = 0.771, p < 0.001) indicating substantial agreement.

This ICT tool using simulated whole-blood samples has a high possibility of being used with real whole blood. Therefore, since there is no need to separate serum, this can be considered an innovative diagnostic tool to replace serum-based ELISA in clinics and field surveys in remote areas where medical facilities are limited.